Below are current clinical trials.403 studies in Hematology
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to evaluate the usefulness of collecting health related quality of life data on newly diagnosed AL amyloidosis patients.
La Crosse, Wis., Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
This study is being done to collect patient data and samples (blood, plasma and tissue) for future research on melanoma.
The purpose of this phase 1b/2 study is to evaluate a safe and tolerable recommended dose for TRC105 when added to standard dose sorafenib in patients with liver cell cancer, then to estimate the overall response rate.
The purpose of this study is to assess the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab for treating patients with stage IV triple negative breast cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ruxolitinib phosphate together may work better in treating patients with stage IV triple negative breast cancer.
This randomized pilot trial studies how well fat emulsion works in preventing hypersensitivity reactions in patients with cancer receiving carboplatin or oxaliplatin. Giving lipids before chemotherapy may prevent some drug reactions from carboplatin or oxaliplatin.
Jacksonville, Fla., Rochester, Minn.
In this study, participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) or relapsed or refractory Richter Syndrome (rrRS) will receive pembrolizumab (MK-3475). The efficacy of pembrolizumab in the treatment of rrPMBCL and rrRS will be evaluated.
The purpose of this study is to compare gemcitabine hydrochloride in combination with AZD 1775 to gemcitabine hydrochloride given alone to treat patients with ovarian, primary peritoneal, or fallopian tube cancer that has returned after a period of time. Gemcitabine hydrochloride may prevent tumor cells from multiplying by damaging their deoxyribonucleic acid (DNA) molecules that contain instructions for the proper development and functioning of cells, which in turn stops the tumor from growing. AZD 1775 may block specific protein activity and may increase the effectiveness of gemcitabine hydrochloride by preventing the protein from repairing damaged tumor cells without causing harm to normal cells. It is not yet known whether gemcitabine hydrochloride with or without AZD1775 may be an effective treatment for recurrent ovarian, primary peritoneal, or fallopian tube cancer.
The purpose of this study is to evaluate the safety and drug/body interactions of ABBV-085, and to determine the recommended future study dose (alone or in combination with standard therapies) for people who have advanced solid tumors.
La Crosse, Wis., Eau Claire, Wis., Rochester, Minn.
This randomized phase II trial studies how well cisplatin works with or without veliparib in treating patients with stage IV triple-negative breast cancer and/or breast cancer (BRCA) mutation-associated breast cancer. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if cisplatin is more effective with or without veliparib in treating patients with triple-negative and/or BRCA mutation-associated breast cancer.
Scottsdale/Phoenix, Ariz., Rochester, Minn.
The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success.
June 10, 2016
- Colborn LK. Office of Access Management. Mayo Clinic, Rochester, Minn. Jan. 28, 2016.
- Translational Research Program. National Cancer Institute. http://trp.cancer.gov/default.htm. Accessed March 17, 2016.
- NCI-designated cancer centers. National Cancer Institute. http://www.cancer.gov/research/nci-role/cancer-centers. Accessed April 22, 2016.
- Mayo Clinic Cancer Center. National Cancer Institute. http://www.cancer.gov/research/nci-role/cancer-centers/find/mayoclinic. Accessed April 22, 2016.
- Cancer Center of Excellence designation. Florida Department of Health. http://www.floridahealth.gov/provider-and-partner-resources/research/cancer-center-of-excellence-award.html. Accessed April 22, 2016.